CME: Identifying and Managing Cancer Therapy-Induced Interstitial Lung Disease (ILD) and Pneumonitis

Identifying and Managing Cancer Therapy-Induced Interstitial Lung Disease (ILD) and Pneumonitis

Guest: Adam M. Brufsky, MD, PhD
Guest: Nina Thomas, MD

Take Post-Test

If you’ve already completed the activity.

Overview
Interstitial lung disease (ILD) is a heterogeneous group of diseases that produce inflammation and fibrosis of the parenchyma, affecting the alveolar, interstitial, and vascular spaces. Drug-induced (DI) ILD is associated with a range of novel targeted therapies for the treatment of multiple cancer types, including immune checkpoint inhibitors, CDK 4/6 inhibitors, EGFR tyrosine kinase inhibitors, HER2 targeted therapies, and mechanistic target of rapamycin inhibitors.
Although management of low-grade or asymptomatic ILD with corticosteroid treatment and/or treatment interruption may slow or reverse ILD progression, higher-grade/symptomatic ILD requires permanent discontinuation of therapy. Therefore, it is critical that the interprofessional care team is prepared to monitor for and detect anti-cancer therapy–induced ILD. This educational activity will review the latest evidence and strategies for the early detection of medication-induced ILD and pneumonitis and appropriate management strategies to overcome these treatment challenges in patients who receive select anti-cancer therapies. Expert thought leaders will present relevant information about cancer therapy–induced ILD and pneumonitis and how to integrate the latest advances into real-world clinical practice regarding differential diagnosis, hallmark signs/symptoms, recommended management strategies, implications of patient/caregiver education, and the essentials of team-based management to optimize patient outcomes.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
1. Identify risk factors and symptoms of drug-induced ILD/pneumonitis in patients treated with anti-cancer therapies known to cause ILD/pneumonitis
2. Evaluate newer classes of agents that may contribute to medication-induced ILD/pneumonitis and recommendations for monitoring, detecting, and managing drug-induced ILD/pneumonitis
3. Implement close monitoring for signs and symptoms of drug-induced ILD/pneumonitis to improve early detection and effective management of ILD
4. Develop patient and caregiver education strategies for symptom monitoring of drug-induced ILD/pneumonitis
Target Audience
This educational activity is designed for US-based academic and community medical oncologists, pulmonologists, pathologists, oncology nurses, oncology nurse navigators, oncology pharmacists, physician assistants, and other oncology team members involved in treating patients at risk for cancer therapy-induced ILD/pneumonitis (ILD/P).
Faculty Disclosure
Disclosure of Conflict of Interest
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:
Adam Brufsky, MD, PhD, reported a financial interest/relationship or affiliation in the form of Consultant: Pfizer, Inc; Novartis Pharmaceuticals Corp; Lilly USA; AstraZeneca Pharmaceuticals LP; Seagen; and Daiichi Sankyo Co, Ltd. Nina Thomas, MD, has no real or apparent conflicts of interest to report.
The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Adrienne N. Nedved, MPA, PharmD, BCOP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.
Accreditation and Credit Designation Statements
ACCREDITED CONTINUING EDUCATION
Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 12/20/2022 PAs should only claim credit commensurate with the extent of their participation.
Credit Designation for Pharmacists
This knowledge-based activity is approved for for 1.0 contact hour of continuing JA4008106-0000-21-084-H01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Provider(s)/Educational Partner(s)
Provided by
Commercial Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo.
Terms of Use
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.
Disclaimer
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation and Request for Credit:
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.
There is no fee for this educational activity.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

- Jacob D. Soumerai, MD
  Peer
- Andrew H. Lipsky, MD
  Peer
2
CME/CE
Optimizing Outcomes for Patients with Relapsed or Refractory CLL/SLL
Optimizing Outcomes for Patients with Relapsed or Refractory CLL/SLL
0.25 credits
Optimizing Outcomes for Patients with Relapsed or Refractory CLL/SLL
0.25 credits
- Shaji K. Kumar, MD
  Peer
- María-Victoria Mateos, MD, PhD
  Peer
3
CME/CE
Keeping Pace in Hematologic Malignancies: Updates from ASCO 2022
Keeping Pace in Hematologic Malignancies: Updates from ASCO 2022
0.25 credits
Keeping Pace in Hematologic Malignancies: Updates from ASCO 2022
0.25 credits
- Cesar Rodriquez Valdes, MD
  Peer
- Amrita Krishnan, MD
  Peer
4
CME/CE
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
0.25 credits
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
0.25 credits
- Amrita Krishnan, MD
  Peer
- Morie Gertz, MD, MACP
  Peer
3
CME/CE
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Relapsed or Refractory Multiple Myeloma
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Relapsed or Refractory Multiple Myeloma
0.25 credits
Keeping Pace in Hematologic Malignancies: Optimizing Treatment Selection in Rel…
0.25 credits